Recent Finacing
Recent Raise
PredictImmune develops and commercializes CE‑marked whole-blood genetic prognostic tests (PredictSURE IBD) that stratify Crohn’s and ulcerative colitis patients at diagnosis and support clinical trial stratification.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at PredictImmune.
